Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals is positioned for upside because its commercial base is gaining traction while multiple pipeline and regulatory catalysts could extend growth beyond today’s approved products. Fanapt remains its largest revenue driver and grew 23% year-over-year to $36M in 2Q26, while HETLIOZ delivered positive Phase 3 data in delayed sleep-wake phase disorder with a 37.1-minute placebo-adjusted improvement and could become the first FDA-approved therapy for that condition if the sNDA succeeds. With $170M in cash and marketable securities as of mid-2026, full-year 2026 revenue guidance of $240M–$290M, and several late-stage readouts and approvals expected in 2026 or early 2027, the company appears capable of funding operations while re-accelerating revenue despite generic pressure.

Vanda Pharmaceuticals is exposed to concentrated commercial risk because revenue depends heavily on FANAPT, HETLIOZ, and PONVORY, while generic competition poses a material threat to HETLIOZ and third-party reimbursement barriers may restrict patient access and market penetration. Its outlook is further weakened by dependence on uncertain FDA approvals for Bysanti, tradipitant, and imsidolimab, where even positive clinical data may still require additional studies and delay commercialization. In addition, patent defense and license protection are critical to preserving exclusivity, and the company may need additional capital as R&D tax credit limits, product liability claims, and uncertain financing terms could pressure cash burn and GAAP earnings.